Company Description
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases.
The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.
Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.
The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019.
The company was incorporated in 2013 and is based in Waltham, Massachusetts.
| Country | United States |
| Founded | 2013 |
| IPO Date | Jul 30, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Vikas Sinha |
Contact Details
Address: 1100 Winter Street Waltham, Massachusetts 02451 United States | |
| Phone | 617 433 2605 |
| Website | allovir.com |
Stock Details
| Ticker Symbol | ALVR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001754068 |
| CUSIP Number | 019818103 |
| ISIN Number | US0198181036 |
| Employer ID | 83-1971007 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Vikas Sinha C.A., CPA, M.B.A. | Chief Executive Officer and Director |
| David L. Hallal | Executive Chairman of the Board |
| Edward Miller J.D. | General Counsel and Secretary |
| Brett R. Hagen | Chief Accounting Officer |
| Dr. Ann M. Leen Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 18, 2025 | 8-K | Current Report |
| Mar 12, 2025 | 8-K | Current Report |
| Mar 7, 2025 | 10-K | Annual Report |
| Feb 28, 2025 | 424B3 | Prospectus |
| Feb 24, 2025 | 144 | Filing |
| Feb 24, 2025 | 144 | Filing |
| Feb 24, 2025 | 144 | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 10, 2025 | EFFECT | Notice of Effectiveness |
| Feb 10, 2025 | 424B3 | Prospectus |